SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Leerink Partners Upgrades Abbott Laboratories to Outperform From In Line

Leerink Partners upgraded Abbott Laboratories to Outperform from In Line and set a $124 price target.

ABT

Related stories